The Mucosal Immune System
Every day, an adult human gut epithelium faces roughly a kilogram of bacteria. It also faces whatever antigens arrive in food. Why does the immune system not launch a full-scale inflammatory attack against breakfast? The answer lies in a specialized branch of adaptive immunity. It operates at wet, exposed surfaces — the mucosal immune system. Mucosal surfaces (gut, airway, urogenital tract, conjunctiva, mammary gland) present a paradox unlike anywhere else in the body. They must remain permeable enough to absorb nutrients and exchange gases. Yet they face the largest microbial and antigenic load an organism ever encounters. A skin-like fortress of tight junctions and dead keratin cannot work here. The epithelium must stay thin and absorptive. Instead, evolution built a distinct, distributed immune organ called mucosa-associated lymphoid tissue (MALT). It runs its own rules for antibody class, transport, and tolerance. This article explains how the mucosal system solves that paradox. It shows how antigen gets sampled without breaching the barrier. It shows how B cells are instructed to make secretory IgA rather than IgG. It explains how that antibody is exported across the epithelium intact. It also shows how the same tissue learns to ignore food and commensal microbes (oral tolerance), while still defending against pathogens. It builds on The Humoral Response — the general antibody-generation machinery. But it bends nearly every one of its rules to fit an environment where the enemy and the food are mixed together in the same lumen. Understanding mucosal immunity matters clinically far beyond the gut. It explains why oral vaccines work differently from injected ones. It explains why IgA deficiency is the most common primary immunodeficiency, yet often nearly asymptomatic. It explains why breastfeeding transfers passive immunity without ever crossing into the infant's bloodstream. It also explains why failures of oral tolerance underlie food allergy, celiac disease, and inflammatory bowel disease.
- MALT (gut = GALT, including Peyer's patches; also NALT, BALT, and mammary/genital tissue) is a diffuse immune organ under every mucosal surface, containing more lymphocytes than the spleen.
- Microfold (M) cells overlying Peyer's patches sample luminal antigen and deliver it to underlying dendritic cells without breaching the epithelial barrier.
- TGF-β, retinoic acid (from gut dendritic cells), and IL-6/IL-5 drive B cells to class-switch preferentially to IgA in mucosal germinal centers.
- Dimeric IgA binds the poly-Ig receptor on the basolateral epithelial surface and is transcytosed to the lumen as secretory IgA (sIgA), which neutralizes pathogens without triggering inflammation.
- Oral tolerance uses regulatory T cells (induced Tregs, Foxp3⁺) and clonal anergy/deletion to prevent immune attack on food antigens and commensal bacteria.
- Breakdown of these mechanisms causes celiac disease, food allergy, inflammatory bowel disease, and explains the logic (and limits) of oral vaccines like the polio and rotavirus vaccines.
At mucosal surfaces the adaptive immune system trades inflammatory power for a non-inflammatory export antibody, secretory IgA, and an active tolerance program — because most of what crosses these surfaces is food or friend, not foe.
The core idea
The mucosal immune system is the collection of lymphoid tissues and immune mechanisms specialized to protect the roughly 400 m² of epithelial surface — gut, respiratory tract, urogenital tract, and exocrine glands — that interfaces directly with the external world. Collectively this tissue is called mucosa-associated lymphoid tissue, MALT, subdivided by location into GALT (gut-associated, including Peyer's patches, the appendix, and isolated lymphoid follicles), NALT (nasopharynx-associated, including tonsils and adenoids), and BALT (bronchus-associated, prominent in some species, less constitutively organized in adult humans). MALT is not a single organ like the spleen; it is a distributed system of organized lymphoid follicles plus diffusely scattered lymphocytes in the epithelium and lamina propria, and in aggregate it contains more lymphocytes than the rest of the immune system combined. The defining molecular signature of mucosal immunity is secretory immunoglobulin A (sIgA). Unlike serum IgG or IgM, sIgA is built to work in a hostile extracellular environment — a river of proteases, low pH, and shear stress — and its job is fundamentally different from a serum antibody's. Serum antibodies frequently work by recruiting complement and Fc-receptor-bearing effector cells to destroy an opsonized target; that would be catastrophic in the gut lumen, where triggering complement or phagocyte activation against the resident microbiota every minute of every day would produce chronic, tissue-destroying inflammation. sIgA instead acts largely by immune exclusion: it binds antigens, toxins, and microbes and prevents them from adhering to or penetrating the epithelium, then is simply washed away in mucus and lumenal flow, without activating complement (IgA is a poor complement activator) or inflammatory cascades. The second defining feature is active tolerance. Given the constant antigenic bombardment from diet and commensal microbiota, default immune activation is not a viable strategy — it would produce constant, damaging inflammation (as seen when this system fails, e.g., in inflammatory bowel disease). Instead the gut immune system is biased by its local cytokine and cellular environment (dominated by regulatory dendritic cells producing TGF-β and retinoic acid) toward generating regulatory T cells and IgA responses rather than inflammatory Th1/Th17 responses, a state maintained unless danger signals (pathogen-associated molecular patterns, tissue damage) override it. This default is called oral tolerance when studied experimentally via fed antigen, but the same logic governs tolerance to the whole commensal microbiota continuously.
Mechanism
Step 1 — Anatomical organization of GALT. The gut wall contains organized lymphoid structures called Peyer's patches, most densely packed in the ileum, each containing B-cell follicles with germinal centers, interfollicular T-cell zones, and an overlying specialized epithelium called the follicle-associated epithelium (FAE). Scattered among ordinary absorptive enterocytes in the FAE are microfold (M) cells, flattened epithelial cells with a thin cytoplasm, few or no microvilli, and no substantial mucus layer, physically deformed on their basal side into a pocket that cradles dendritic cells, T cells, and B cells directly underneath.
Step 2 — Antigen sampling without barrier breach. M cells transcytose particulate antigen, whole bacteria, and viruses from the gut lumen directly into this basal pocket by receptor-mediated and non-specific endocytosis, delivering intact antigen to resident dendritic cells within minutes — without ever exposing the antigen to the bloodstream. Separately, specialized CX3CR1⁺ mononuclear phagocytes in the lamina propria extend dendrites between enterocyte tight junctions (without disrupting them) directly into the lumen to sample antigen — a mechanism first well documented in mouse small intestine. Dendritic cells activated this way migrate to the mesenteric lymph nodes and the Peyer's patch T-cell zones.
Step 3 — Imprinting a mucosal, non-inflammatory phenotype. Gut-resident dendritic cells are conditioned by the local environment (epithelium-derived TSLP, retinoic acid metabolized from dietary vitamin A via the enzyme RALDH2) to be tolerogenic by default: upon presenting antigen to naive T cells, they preferentially induce Foxp3⁺ induced regulatory T cells (iTregs) rather than inflammatory effectors, and they instruct B cells toward IgA class switching. Retinoic acid produced by these dendritic cells also upregulates the gut-homing receptors α4β7 integrin and CCR9 on activated T and B cells, so that lymphocytes primed in gut-draining tissue return specifically to gut lamina propria — the basis of the "common mucosal immune system" concept, in which priming at one mucosal site (e.g., Peyer's patch) can seed effector cells to distant mucosal surfaces sharing the same homing receptors.
Step 4 — Class switching to IgA. In the Peyer's patch germinal center, B cells undergo class-switch recombination directed to the IgA constant region gene, driven chiefly by TGF-β (produced by mucosal dendritic cells and T cells) together with IL-5, IL-6, and IL-10, and in some settings by T-cell-independent signals — dendritic-cell-derived BAFF and APRIL engaging TACI on B cells, allowing IgA switching even without full T-cell help, which helps explain rapid IgA responses to commensal polysaccharides. The result is IgA-secreting plasma cells that migrate out to the lamina propria under the homing instructions from Step 3.
Step 5 — Making the dimer. Unlike serum IgA (mostly monomeric), mucosal plasma cells secrete IgA as a dimer (two monomers linked tail-to-tail) joined by a small cysteine-rich polypeptide called the J chain, produced by the same plasma cell.
Step 6 — Transcytosis via the poly-Ig receptor. The epithelial cells lining the gut and other mucosal surfaces constitutively express the polymeric immunoglobulin receptor (pIgR) on their basolateral membrane. Dimeric IgA binds pIgR, and the complex is endocytosed and transported across the cell (transcytosis) to the apical/luminal surface. There, pIgR is proteolytically cleaved: the antibody keeps a fragment of the receptor called the secretory component, and the whole complex — dimeric IgA + J chain + secretory component — is released into the lumen as secretory IgA (sIgA). The secretory component is not a mere leftover; it is heavily glycosylated and shields sIgA from luminal proteases, giving it a functional half-life in the gut lumen far longer than an equivalent unprotected antibody, and it also helps sIgA adhere to the mucus layer.
Step 7 — Immune exclusion, and effects at all three barrier compartments. sIgA in the lumen (i) agglutinates bacteria and viruses, preventing adhesion to epithelial receptors, (ii) neutralizes toxins and enzymes, (iii) can trap antigens within mucus for clearance by peristalsis, and — a distinct and less appreciated function — (iv) IgA can also bind antigen intracellularly during transcytosis (neutralizing replicating virus inside the epithelial cell itself) and (v) can be actively secreted basolaterally to intercept antigen that has already breached the epithelium, exporting it back into the lumen ("backwards" transport). Because IgA does not readily fix complement via the classical pathway and interacts poorly with most Fc receptors that trigger degranulation, these actions occur largely without an inflammatory response.
Step 8 — Oral tolerance. When antigen is delivered by the oral route (as opposed to systemic injection or infection with adjuvant/danger signals), the default outcome is tolerance rather than immunity, through two non-exclusive mechanisms depending on antigen dose: low-dose feeding favors generation of antigen-specific Foxp3⁺ iTregs and other regulatory populations (Tr1 cells producing IL-10, Th3 cells producing TGF-β) that actively suppress subsequent immune responses to that antigen, including at distant, non-gut sites; high-dose feeding favors clonal anergy or clonal deletion of antigen-reactive T cells. This tolerance is antigen-specific, systemic (protects against later injected challenge with the same antigen, not just oral re-exposure), and is the physiological basis by which the immune system tolerates the ~10¹³–10¹⁴ commensal bacteria in the gut and daily dietary antigens without chronic inflammation.
The evidence
Kilian, Brandtzaeg, and the identification of secretory component and pIgR (1960s–70s). Early biochemists studying human external secretions (saliva, colostrum, tears) noticed that the IgA found there had a higher molecular weight and different physicochemical behavior than serum IgA, and that it was resistant to proteolysis in a way serum IgA was not. Work by Thomas B. Tomasi and John Bienenstock in the 1960s established that this "exocrine" IgA existed as a dimer associated with an additional protein — later shown by Per Brandtzaeg's group and others to be a cleaved fragment of an epithelial transport receptor, which was named the secretory component. This directly demonstrated that mucosal IgA is not simply serum IgA leaking through damaged epithelium; it is actively assembled and exported by a dedicated receptor-mediated transcytosis pathway, distinguishing mucosal humoral immunity as a mechanistically separate arm of the antibody response — the founding observation of the whole field.
Mowat and the classic oral tolerance experiments (1980s, building on Chase and Wells earlier in the 20th century). The core phenomenon — that feeding an antigen protects against later immunization with the same antigen — was first documented by Henry Wells in 1911 for food proteins and rigorously characterized immunologically by Merrill Chase in 1946, who showed that guinea pigs fed a contact-sensitizing chemical could not later be sensitized to it by skin application (a phenomenon called "Chase-Sulzberger" or "Chase's" tolerance). Allan Mowat and colleagues in the 1980s systematically dissected this using ovalbumin (OVA)-fed mice: mice fed OVA before systemic immunization with OVA in adjuvant showed markedly suppressed delayed-type hypersensitivity and antibody responses compared to unfed controls, and this suppression could be transferred to naive mice using T cells alone from tolerized donors, proving the tolerance was an active, T-cell-mediated regulatory process rather than mere failure to respond. This experiment was pivotal because it distinguished true active tolerance (transferable suppression) from passive non-responsiveness (which would not transfer), establishing the existence of what we now call regulatory T cells generated by oral antigen exposure — years before Foxp3 or CD25⁺ Tregs were molecularly characterized by Sakaguchi and colleagues.
Owen and Jones — direct visualization of M cells (1974). Using scanning and transmission electron microscopy of rabbit Peyer's patches, Robert Owen and Andrew Jones showed that the follicle-associated epithelium contains a morphologically distinct cell type with sparse microvilli, a thin apical cytoplasm, and a deep basal invagination housing lymphocytes — the M cell — and demonstrated by tracer studies (ferritin particles instilled into the gut lumen) that these particles were taken up specifically by M cells and delivered to the underlying pocket lymphocytes within minutes, while adjacent absorptive enterocytes did not take up the tracer. This provided the direct structural and functional proof that antigen sampling in the gut occurs through a specialized transcellular route, resolving the puzzle of how intact antigen (as opposed to fully digested nutrients) reaches gut lymphoid tissue.
The clinical "experiment of nature": selective IgA deficiency. Selective IgA deficiency, the most common primary immunodeficiency (roughly 1 in 500 people of European descent), shows that IgA, while important, is not solely responsible for mucosal defense — many affected individuals are largely asymptomatic, because compensatory secretory IgM (also transported by pIgR, sharing the J-chain-mediated recognition) partially substitutes at mucosal surfaces. This natural knockout experiment sharpened the field's understanding that pIgR-mediated transport, not IgA specifically, is the essential engine of mucosal humoral defense, and that redundancy is built into the system.
Worked examples
Example 1 — Reading an IgA-deficiency pedigree and predicting antibody class at the mucosa. A patient with selective IgA deficiency (serum IgA below 7 mg/dL, normal IgG and IgM) presents with recurrent sinopulmonary infections but no gut symptoms, and their asymptomatic sibling has identical serum IgA levels. Question: why do some IgA-deficient individuals stay well while others develop recurrent infections, and what predicts the difference? Reasoning: pIgR transports any J-chain-containing polymeric immunoglobulin, not IgA exclusively; in most IgA-deficient people, plasma cells compensate by secreting polymeric IgM with J chain, which is transcytosed via the same pIgR pathway and substitutes functionally for sIgA at the mucosal surface, especially in the gut, where the microbiota provides constant stimulation for this compensatory response. The airway mucosa has comparatively less baseline antigenic stimulation and more marginal effective sIgM compensation, so respiratory infections are more common than gut infections in this condition — consistent with the actual clinical pattern (recurrent sinopulmonary infection is the dominant complaint, gastrointestinal infection less so). This example shows the general principle: mucosal antibody function depends on pIgR-mediated transport capacity, and any polymeric Ig with a J chain can be substituted into that pathway.
Example 2 — Dose-dependent outcome of oral antigen exposure (a clinical/immunological calculation). Suppose a mouse experiment feeds three groups different total doses of ovalbumin (OVA) over one week, then challenges all groups with OVA plus adjuvant injected systemically two weeks later, and measures serum anti-OVA IgG titer (arbitrary ELISA units) and Foxp3⁺ Treg frequency in mesenteric lymph nodes:
| Group | OVA fed (total, mg) | Anti-OVA IgG titer after challenge | MLN Foxp3⁺ Treg (%) |
|---|---|---|---|
| A (no feeding, control) | 0 | 1000 | 4% |
| B (low dose) | 1 | 150 | 22% |
| C (high dose) | 50 | 80 | 9% |
Question: interpret this pattern mechanistically. Reasoning: Group A, unprimed, mounts a full antibody response upon adjuvant challenge (baseline of 1000 units). Group B, fed a low dose, shows the largest drop in antibody titer (to 150, an ~85% reduction) accompanied by the largest rise in Foxp3⁺ Tregs (22%, more than five-fold over control) — consistent with the low-dose mechanism of oral tolerance, active generation of regulatory T cells that suppress the subsequent response. Group C, fed a much higher dose (50 mg), also shows strong suppression of antibody titer (80 units, even lower than Group B) but a comparatively modest rise in Tregs (9%) — consistent with the high-dose mechanism, which works predominantly through clonal anergy/deletion of antigen-reactive T cells rather than active regulatory cell expansion. The key quantitative signature that separates the two mechanisms is the Treg frequency, not the degree of suppression itself: strong suppression with high Treg induction implicates active regulation; strong suppression with low Treg induction implicates deletion/anergy. This dose-dependence is why oral tolerance protocols in both experimental models and (experimentally, in humans) immunotherapy trials must be carefully titrated — too little antigen may not tolerize, and different doses engage genuinely different cellular mechanisms.
Common misconceptions & traps
| Misconception | Correction |
|---|---|
| "IgA is a weak antibody because it doesn't fix complement well." | IgA's poor complement activation is a feature, not a weakness — it allows pathogen exclusion without inflammatory collateral damage, appropriate for a surface facing constant, mostly harmless antigenic exposure. |
| "Oral tolerance means the gut immune system is 'switched off.'" | The gut mounts vigorous IgA responses to the same microbiota it tolerates at the T-cell level; tolerance and active humoral defense operate simultaneously and are not the same axis. |
| "Secretory IgA is just serum IgA that leaked across a damaged epithelium." | sIgA is actively assembled (J chain + dimer) and transported through an intact epithelium via a dedicated receptor (pIgR); its production requires no barrier breach at all. |
| "M cells are simply weak spots in the barrier that pathogens exploit." | M cells are functionally essential immune-sampling structures, not accidental gaps — though several pathogens (e.g., Salmonella, poliovirus) have indeed evolved to exploit M-cell transcytosis for invasion, this is a hijacking of a designed sampling pathway, not evidence the pathway itself is a flaw. |
| "Since IgA deficiency is common and usually mild, IgA must not matter much." | IgA matters, but the system carries redundancy (secretory IgM via the same pIgR); the mildness of most IgA deficiency demonstrates redundancy, not unimportance. |
| "Oral tolerance is only relevant to allergy prevention." | Oral tolerance is the default state maintaining non-response to the entire diet and commensal microbiota continuously; food-allergy prevention is one clinically visible consequence, not the whole phenomenon. |
:::warning[The most dangerous confusion: mucosal tolerance and mucosal immunity are not opposites happening in different places — they are two outputs of the same tissue, allocated by antigen context.] A vaccine antigen delivered orally with the right adjuvant/context can generate protective sIgA and effector T cells at the very same gut sites that tolerate dietary protein; the deciding factor is not location but the presence of "danger" signals (pathogen-associated molecular patterns, tissue damage, adjuvant) that override the default tolerogenic dendritic-cell program. Assuming mucosal exposure always equals tolerance leads to serious misunderstanding of both oral vaccine design and the pathogenesis of celiac disease, where a dietary antigen (gluten-derived gliadin peptides) is inappropriately treated as dangerous.
The scientist behind it
Much of the molecular logic of mucosal immunity — the secretory component, the J chain, the transcytotic pathway — was worked out through the mid-20th-century convergence of clinical chemists studying human secretions and immunologists studying antibody structure. One central figure is the Norwegian immunologist Per Brandtzaeg, whose decades of work at the University of Oslo, beginning in the late 1960s, used immunohistochemistry on human salivary gland, gut, and tonsil tissue to map exactly where pIgR is expressed, how it is cleaved, and how J-chain-containing dimeric IgA and pentameric IgM are selectively captured for transport — turning a biochemical curiosity (an oddly heavy IgA in saliva) into a fully worked cell-biological pathway. Brandtzaeg's laboratory also carried out much of the anatomical mapping of human MALT (Peyer's patches, tonsils, salivary and lacrimal glands, mammary gland) that established the concept of a distributed "common mucosal immune system" with shared homing rules — work that still underlies current models of mucosal vaccine design.
Origins · 1 minPer Brandtzaeg and how this was discovered
Brandtzaeg trained as a physician and pathologist before turning to the then-nascent question of how antibodies reach external secretions. Working largely with human tissue rather than mouse models — a deliberate methodological choice that gave his findings unusual direct clinical relevance — he combined immunofluorescence, electron microscopy, and biochemical fractionation to characterize secretory component, J chain, and the transport receptor across dozens of human mucosal and glandular tissues over a five-decade career, publishing foundational descriptions of the human mucosal immune system used in clinical immunology and vaccinology to this day.
Where this matters today
Oral and mucosal vaccine design. The Sabin oral poliovirus vaccine and the rotavirus vaccines (RotaTeq, Rotarix) work by exploiting M-cell uptake and Peyer's patch priming to generate protective sIgA at the very surface pathogens use to enter, something an injected vaccine (which mainly generates serum IgG) does less efficiently for enteric pathogens. Understanding pIgR and the germinal-center switch to IgA has directly shaped the design of mucosal adjuvants (e.g., derivatives of cholera toxin B subunit) intended to boost sIgA responses to co-administered antigens.
Celiac disease and food allergy as tolerance failures. Celiac disease represents an inappropriate loss of tolerance to a dietary antigen (gliadin peptides from wheat gluten), driven partly by tissue transglutaminase-modified gliadin peptides that bind HLA-DQ2/DQ8 unusually well and provoke a Th1-dominated inflammatory response instead of the normal regulatory response; food allergy represents a related failure in which IgE rather than IgA/tolerance dominates the response to food antigen. Both illustrate why understanding the default tolerogenic wiring of gut dendritic cells and Tregs matters for treating and potentially preventing these diseases — including current oral immunotherapy protocols for peanut and other allergies, which are direct clinical applications of dose-titrated oral tolerance principles.
Inflammatory bowel disease. Crohn's disease and ulcerative colitis both involve breakdown of the normal balance between regulatory and inflammatory responses to commensal microbiota, and much current IBD research directly extends the Peyer's patch/dendritic-cell/Treg framework described here, including therapeutic strategies (e.g., anti-integrin biologics targeting α4β7, the very gut-homing receptor induced by retinoic acid) that block lymphocyte trafficking to inflamed gut tissue.
Passive immunity via breast milk. Colostrum and breast milk are rich in secretory IgA produced by plasma cells that have migrated to the mammary gland under the same gut-imprinted homing signals (the entero-mammary link), delivering maternal sIgA against gut pathogens the mother has encountered directly to the infant's gut lumen — protecting the neonate's mucosa without ever entering the neonatal bloodstream, a clean example of the whole pathway (Peyer's patch priming → IgA switch → homing → pIgR transcytosis) operating across two individuals.
Understanding pathogen strategies at the barrier, a theme picked up more fully under Host-Pathogen Interactions: several major pathogens (Salmonella Typhi, poliovirus, reovirus, HIV via specific mechanisms in genital mucosa) specifically exploit M-cell transcytosis or disrupted mucosal tolerance to gain entry, meaning the very sampling system built for defense doubles as an invasion route that pathogens have evolved to hijack.
Ask the tutor: How does the gut immune system decide, on a case-by-case basis, whether a given antigen should trigger tolerance or an active IgA/inflammatory response?
Why doesn't the gut immune system attack the trillions of commensal bacteria living in it?
Multiple layers prevent this. Physically, mucus and antimicrobial peptides keep most bacteria away from the epithelium itself. Locally, gut dendritic cells are conditioned by retinoic acid and other signals to be tolerogenic by default, inducing Foxp3⁺ regulatory T cells rather than inflammatory effectors when they present commensal antigens. Humorally, secretory IgA binds and agglutinates bacteria without activating complement or inflammatory Fc receptors, so bacteria are excluded rather than attacked. This is not simple ignorance of the microbiota — B and T cells are demonstrably reactive to commensal antigens — but active, continuously maintained regulation. When this regulation fails, as in inflammatory bowel disease, the result is chronic inflammatory attack on the normally tolerated microbiota.
How is secretory IgA different from ordinary serum IgA?
Serum IgA is mostly monomeric and circulates in blood, where it plays a comparatively minor role. Secretory IgA is a dimer, held together by a J chain, and additionally carries a secretory component — a fragment of the polymeric immunoglobulin receptor (pIgR) that remains attached after the antibody is transported across epithelial cells and released into the mucus lining the lumen. The secretory component protects sIgA from digestive and bacterial proteases, letting it function for extended periods in the gut lumen, and it also helps anchor sIgA within the mucus layer. Functionally, sIgA works mainly by immune exclusion (blocking adhesion and neutralizing toxins) rather than by recruiting inflammatory effector mechanisms, which distinguishes its biological role sharply from serum antibody classes.
What exactly is oral tolerance, and is it the same as immune ignorance?
Oral tolerance is active, antigen-specific immunological non-responsiveness induced by exposing the immune system to antigen via the gut, first documented experimentally by feeding proteins to animals before systemic immunization. It is not ignorance or a failure to detect antigen — the immune system does detect fed antigen, but in the absence of danger signals, gut dendritic cells default to inducing regulatory T cells (at low antigen doses) or anergy/deletion of reactive T cells (at high doses) rather than inflammatory immunity. This tolerance is systemic: an animal fed an antigen becomes resistant to being immunized against that same antigen later by injection anywhere in the body, which is why the phenomenon was recognized as a true regulatory state rather than a local, gut-only effect.
How do oral vaccines exploit mucosal immunology differently from injected vaccines?
Injected vaccines mainly access systemic lymphoid tissue and generate serum IgG, which protects against bloodstream and tissue infection but is transported into mucosal secretions only weakly. Oral vaccines, such as the Sabin poliovirus vaccine or rotavirus vaccines, are taken up by M cells overlying Peyer's patches, prime B cells in gut-associated lymphoid tissue, and generate IgA-secreting plasma cells that home specifically back to mucosal surfaces (via α4β7 integrin and CCR9, induced by retinoic acid during priming). This produces protective secretory IgA directly at the mucosal entry point pathogens use, which is often more effective at blocking initial infection at that surface than serum IgG alone, though oral vaccines must also overcome gastric acid, dilution, and potential interference from pre-existing gut antibody or other enteric microbes.
What goes wrong immunologically in celiac disease?
Celiac disease is fundamentally a failure of oral tolerance to a specific dietary antigen: peptides derived from gluten, particularly gliadin. In genetically susceptible individuals (carrying HLA-DQ2 or HLA-DQ8), the enzyme tissue transglutaminase deamidates gliadin peptides, increasing their binding affinity for these HLA molecules and promoting a strong, inflammatory (Th1-dominated) T-cell response rather than the regulatory response normally generated toward dietary protein. This drives chronic inflammation and villous atrophy in the small intestine. It is instructive precisely because it shows the same gut immune machinery that normally tolerizes food can, under the wrong genetic and biochemical circumstances, misclassify a dietary antigen as dangerous and mount a damaging inflammatory response instead.
Do all mucosal surfaces use the same rules, or does the gut differ from the lung and other sites?
The core molecular machinery — pIgR-mediated transcytosis, J-chain-linked dimeric IgA, mucosal dendritic-cell conditioning, and regulatory T-cell induction — is shared across mucosal sites, which is why immunologists speak of a "common mucosal immune system" in which priming at one site can seed IgA-secreting plasma cells to distant mucosal tissues sharing the same homing receptors (this underlies, for example, the entero-mammary link supplying breast milk IgA from gut-primed plasma cells). However, the balance of tolerance versus active defense differs by site and antigen load: the gut, facing constant dietary and microbial antigen, is strongly biased toward tolerance by default, while the respiratory mucosa, more often encountering inhaled pathogens without an accompanying "food" signal, shows somewhat less baseline tolerogenic bias, though the same molecular toolkit is used throughout.
Why is IgA a poor activator of the classical complement pathway, and why does that matter?
IgA's constant region does not efficiently engage C1q, the complement component that initiates the classical pathway, and IgA also interacts weakly with most Fc receptors on inflammatory effector cells such as neutrophils and macrophages (with some tissue-specific exceptions, e.g., FcαRI on certain phagocytes). This matters because mucosal surfaces face constant, high-volume antigen exposure from harmless food and commensal microbes; an antibody that triggered complement or phagocyte activation on every encounter would produce continuous, tissue-damaging inflammation at the barrier. By binding and excluding antigen without recruiting these inflammatory cascades, IgA allows the mucosal immune system to maintain a high level of antigen-specific defense while keeping the epithelium in a low-inflammation, functionally intact state suitable for ongoing digestion and gas exchange.